Carine Chaleteix

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

Thierry Façon, Jean Yves Mary, Cyrille Hulin et al. · The Lancet · 2007 · 870 citations

Medicine, Hematology, Oncology +17

Prospective Evaluation of Magnetic Resonance Imaging and [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study

Philippe Moreau, Michel Attal, Denis Caillot et al. · Journal of Clinical Oncology · 2017 · 320 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

Philippe Moreau, Hervé Avet‐Loiseau, Thierry Façon et al. · Blood · 2011 · 302 citations

Medicine, Hematology, Oncology +17

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Philippe Moreau, Cyrille Hulin, Margaret Macro et al. · Blood · 2016 · 276 citations · Full text

Medicine, Oncology, Hematologic Oncology +8

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Laurent Garderet, Simona Iacobelli, Philippe Moreau et al. · Journal of Clinical Oncology · 2012 · 188 citations · Full text

Medicine, Hematology, Pharmacotherapy +17